CliffBio
small molecule

SAMSCA

TOLVAPTAN

Loss of exclusivityApril 2030latest FDA-listed patent expiry
CompanyOtsuka Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand nameSAMSCA
Active ingredientTOLVAPTAN
Strength30MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2009
Marketing statusRX

Listed patents

PatentExpiresType
10905694April 2030product
8501730September 2026substance

More from Otsuka Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SAMSCA patent cliff — loss of exclusivity April 2030 | CliffBio